Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Technical Presentation (November 2023)
6 slides from Amplia Therapeutics's technical presentation, November 2023
Slide 1: CT511 - A phase 1 trial of AMP945, a FAK inhibitor, in healthy volunteers
CT511 - A phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers John Lambert*, Christopher J. Burns, Mark Devlin, Nicole Kruger, Jason Lickliter, Mark Sullivan, Warwick Tong. Amplia Therapeutics, Melbourne, Australia, NMK Consulting, Melbourne, Austra
Slide 2: AMP945 - a highly potent and selective inhibitor of focal adhesion kinase (FAK)
AMP945 - a highly potent and selective inhibitor of focal adhesion kinase (FAK) • FAK is a non-receptor tyrosine kinase with key roles in a variety of cellular processes, in particular those related to the adhesion and migration of many cell types Preclinical safety Phase 1 trial in • Multiple studi
Slide 3: Phase 1 trial design
Phase 1 trial design Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h post-dose on Days 1 and 7 Pre-dose on Days 2-6 3 ANZCTR: ACTRN12620000894998
Slide 4: Results – plasma pharmacokinetics of AMP945
Results – plasma pharmacokinetics of AMP945 Day 7 AUC0-inf (h*ng/mL) Indicates tissue-wide distribution 4
Slide 5: Results – Pharmacodynamics and safety
Results – Pharmacodynamics and safety • No serious or severe TEAEs, nor any TEAEs leading to study withdrawal (majority of TEAEs reported were mild) • There were no dose-related trends observed in the reporting of TEAEs • No TEAEs were considered probably or definitely related to AMP945: • No change
Slide 6: Conclusions - Phase 1 trial of AMP945
Conclusions - Phase 1 trial of AMP945 • AMP945, a selective FAK inhibitor, was safe and well tolerated across SAD (15 to 125 mg) and MAD (25 to 100 mg) cohorts in healthy volunteers. • No serious adverse events or withdrawals • No trends observed in AE reporting, no shifts in clinical laboratory, vi
Amplia Therapeutics — Technical Presentation (November 2023) on 6ix